Published:
Key Takeaways
- Blue Goat Cyber released "Cracking the Code," a white paper guiding medical device premarket cybersecurity success.
- The paper helps manufacturers navigate evolving FDA cybersecurity requirements and avoid submission rejections.
- Authored by Blue Goat Cyber CEO Christian Espinosa, it provides actionable strategies for device security.
- "Cracking the Code" addresses new FDA mandates, including threat models, SBOMs, and post-market monitoring.
- This resource is crucial for streamlining medical device compliance amidst increasing interconnectedness.
- Understanding FDA Cybersecurity Expectations: Section 524B requires covered cyber device submitters to provide an SBOM, a postmarket monitoring and coordinated disclosure plan, and cybersecurity processes including updates and patches. The FDA’s February 3, 2026 final guidance recommends supporting evidence, including threat models, and primarily aligns the guidance with the QMSR. The white paper provides implementation tips.
- Secure Product Development Frameworks: Discover how early integration of cybersecurity into the design phase can save time and costs while enhancing patient safety.
- Top Five Reasons for FDA Submission Rejections: Insights into common pitfalls, such as inadequate threat modeling and risk assessments, help manufacturers avoid costly delays.
- Best Practices for Third-Party Penetration Testing: Understand the FDA’s preference for independent evaluations and learn how to select the right testing partner.
SCOTTSDALE, AZ, UNITED STATES, November 15, 2024
Blue Goat Cyber, a leading provider of cybersecurity solutions for medical device manufacturers, is excited to announce the release of its latest white paper, “Cracking the Code: Insider Cybersecurity Insights for Medical Device Premarket Success.” This invaluable resource is now available for download on the Blue Goat Cyber website at www.bluegoatcyber.com.
Sources & references
Primary sources cited in this article. Links open in a new tab.
- February 3, 2026 final guidance- U.S. FDA